MedDataX Logo

Survey Conducted Among Early Breast Cancer Patients Treated With Arimidex for Evaluation of Treatment Adherence

NCT ID: NCT01081509

Last Updated: 2011-11-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1077 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-03-31

Study Completion Date

2011-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to assess the patient's perception about and willingness to take his or her medication and the influencing factors interfering with taking medication.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Early breast cancer
* Post menopausal
* Adjuvant hormonal Arimidex therapy
Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Zsolt Horvath, M.D., Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Hungarian National Institute of Oncology

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Site

Balatonföldvár, , Hungary

Site Status

Research Site

Békéscsaba, , Hungary

Site Status

Research Site

Budapest, , Hungary

Site Status

Research Site

Debrecen, , Hungary

Site Status

Research Site

Dombóvár, , Hungary

Site Status

Research Site

Gyöngyös, , Hungary

Site Status

Research Site

Győr, , Hungary

Site Status

Research Site

Gyula, , Hungary

Site Status

Research Site

Kaposvár, , Hungary

Site Status

Research Site

Kecskemét, , Hungary

Site Status

Research Site

Miskolc, , Hungary

Site Status

Research Site

Mosdós, , Hungary

Site Status

Research Site

Nagyatád, , Hungary

Site Status

Research Site

Nyíregyháza, , Hungary

Site Status

Research Site

Orfű, , Hungary

Site Status

Research Site

Pápa, , Hungary

Site Status

Research Site

Pécs, , Hungary

Site Status

Research Site

Szeged, , Hungary

Site Status

Research Site

Szekszárd, , Hungary

Site Status

Research Site

Szentes, , Hungary

Site Status

Research Site

Székesfehérvár, , Hungary

Site Status

Research Site

Szombathely, , Hungary

Site Status

Research Site

Veszprém, , Hungary

Site Status

Research Site

Zalaegerszeg, , Hungary

Site Status

Research Site

Zirc, , Hungary

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Hungary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NIS-OHU-ARI-2010/1

Identifier Type: -

Identifier Source: org_study_id